Eikon Therapeutics filed for a U.S. initial public offering, a move framed in coverage as a bellwether for whether renewed biotech optimism can support listings. Company filings position Eikon — a spatial biology/biophysics focused firm — to tap public markets to expand discovery platform capabilities. Market watchers flagged the filing as an early litmus test for 2026 equity demand.